TrianglePD-1/PD-L1 inhibitor monotherapy - 4… (NCT07630168)
PD-1/PD-L1 inhibitor monotherapy - 4 cycles before 12:00PM trial for Lung Cancer (NCT07630168). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with metastatic non-small cell lung cancer or resectable head-and-neck squamous cancer who qualify for standard checkpoint immunotherapy. Recent checkpoint treatment and steroids that cannot be stopped can exclude participation.
The idea: test whether infusion time changes cancer outcomes. Random assignment schedules PD-1/PD-L1 treatment before noon or after 3 p.m.: four cycles for lung cancer, two for head-and-neck cancer. Researchers measure lung-cancer progression or tumor response at surgery, respectively.
This phase 2 study plans 238 patients. UNC’s Shetal Patel leads it in Chapel Hill, the single recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.